Vancouver, BC-based Burcon NutraScience Corp, an R&D company developing a portfolio of composition, application and process patents around its plant protein extraction and purification technology, announced today that it intends to issue on a private placement basis, up to 1,800,000 Units at a price of C$1.85 per Unit for gross proceeds of about C$3,330,000. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more


Completion of the private placement is subject to regulatory approval.


Each Unit will consist of one common share and one non-transferable share purchase warrant. Each warrant will entitle the holder to acquire one common share at a price of C$1.85 (US$1.17) per share for a period of two years from the date of issue of the Units. The Units will be subject to a four-month hold period under CDNX policy and applicable securities legislation and policy.


Johann F. Tergesen, president and COO, revealed that the net proceeds from the private placement will be used to:


·Initiate engineering development, further refine Burcon’s protein extraction and purification technology and pursue new related products,

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

·Pursue functionality development initiatives relating to Burcon’s proteins,


·Initiate nutrition profiling of Burcon’s proteins,


·Further accelerate Burcon’s patent activities,


·Prepare for regulatory approval of Burcon’s proteins for human consumption,


·Hire additional scientific personnel, and


·Provide general working capital.


Burcon has been advised that insiders intend to purchase approximately 700,000 Units from the placement. The placement is non-brokered and no commission or finder’s fee is payable by Burcon.